Phase III X-TOLE2 data support azetukalner filing in focal onset seizures
Xenon Pharmaceuticals reported positive Phase III X-TOLE2 results for azetukalner in focal onset seizures. The company plans an FDA new drug application in Q3 2026.
Xenon Pharmaceuticals Inc.
CompanyAlso known as: Xenon Pharmaceuticals
Company Profile
Xenon Pharmaceuticals is a neuroscience-focused biopharmaceutical company dedicated to drug discovery, clinical development, and commercialization of life-changing therapeutics. Its pipeline includes azetukalner and other ion-channel programs for epilepsy, mood disorders, and pain.
- Website
- https://xenon-pharma.com
- Headquarters
- Burnaby, British Columbia, Canada
- Founded
- 1996
- Stock Ticker
- NASDAQ:XENE
Related News
FDA Clears First-in-Human Trial of Allogeneic Cell Therapy for Drug-Resistant Epilepsy
The FDA has authorized the first human trial of an allogeneic stem cell therapy for epilepsy, developed by Shanghai-based Unixell Biotechnology. The therapy uses donor-derived stem cells to produce GABA and suppress seizures in drug-resistant patients.
Bipolar Depression Pipeline Expands With 10+ Therapies in Development Across 8+ Companies
The bipolar depression treatment pipeline includes over 10 therapies from 8+ companies, with recent Phase 3 trials initiated for azetukalner and multiple emerging drugs targeting novel pathways expected to launch by 2036.
Xenon Pharmaceuticals to Report Phase 3 Epilepsy Trial Results for Azetukalner
Xenon Pharmaceuticals will announce topline data from its Phase 3 X-TOLE2 study of azetukalner in patients with focal onset seizures on March 9, 2026, during a conference call at 8:00 a.m. ET.
Related Clinical Trials
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07217860 |
An Open-label Study of Azetukalner in Bipolar I or II Depression (X-CEED-OLE) |
ENROLLING_BY_INVITATION | PHASE3 |
| NCT07172516 |
A Randomized Study of Azetukalner Versus Placebo in Depressive Episodes Associated With Bipolar I or II Disorder (Bipolar Depression) |
RECRUITING | PHASE3 |
| NCT07076407 |
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder (X-NOVA3) |
RECRUITING | PHASE3 |
| NCT06922110 |
An Open-Label Study of Azetukalner in Major Depressive Disorder |
ENROLLING_BY_INVITATION | PHASE3 |
| NCT06775379 |
A Randomized Study of Azetukalner Versus Placebo in Major Depressive Disorder |
RECRUITING | PHASE3 |
| NCT05718817 |
An Open-label Study of XEN1101 in Epilepsy |
ENROLLING_BY_INVITATION | PHASE3 |
| NCT05716100 |
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures (X-TOLE3) |
RECRUITING | PHASE3 |
| NCT05667142 |
A Study to Evaluate XEN1101 as Adjunctive Therapy in Primary Generalized Tonic-Clonic Seizures |
RECRUITING | PHASE3 |
| NCT05614063 |
A Randomized Study of XEN1101 Versus Placebo in Focal-Onset Seizures |
COMPLETED | PHASE3 |
| NCT05376150 |
A Study to Evaluate the Safety, Tolerability and Efficacy of XEN1101 in Major Depressive Disorder |
COMPLETED | PHASE2 |